- Six insiders sold Sangamo BioSciences stock within one month.
- The stock was not purchased by any insiders in the month of intensive selling.
- Two of these six insiders decreased their holdings by more than 10%.
Sangamo BioSciences, Inc., is a clinical stage biopharmaceutical company that engaged in the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.